Intraperitoneal injection of genetically modified, human mesothelial cells for systemic gene therapy

Human Gene Therapy

Volumn 8, Issue 16, 1997, Pages 1867-1879

  Murphy, J O Ellen ^a   Rheinwald, James G ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; HUMAN GROWTH HORMONE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL DIVISION; CELL SURVIVAL; CRYOPRESERVATION; GENE THERAPY; HUMAN; HUMAN CELL; MESOTHELIUM CELL; NEEDLE BIOPSY; NONHUMAN; NUDE MOUSE; PERITONEAL FLUID;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 0030711645     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.16-1867     Document Type: Article

References (7)

1. ABU-HIJLEH, M.F., HABBAL, O.A., and MOQATTASH, S.T. (1995). The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J. Anat. 186, 453-467.
2. BANDARA, G., MUELLER, G.M., GALEA-LAURI, J., TINDAL, M.H., GEORGESCU, H.I., SUCHANEK, M.K., HUNG, G.L., GLORIOSO, J.C., ROBBINS, P.D., and EVANS, C.H. (1993). Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc. Natl. Acad. Sci. USA 90, 10764-10768.
3. BARAGI, V.M., RENKIEWICZ, R.R., JORDAN, H., BONADIO, J., HARTMAN, J.W., and ROESSLER, B.J. (1995). Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation. J. Clin. Invest. 96, 2454-2460.
4. BARRE, E., and LEIDEN, J.M. (1991). Systemic delivery of recombinant proteins by genetically modified myoblasts. Science 254, 1507-1509.
5. BECKER, T.C., NOEL, R.J., COATS, W.S., GOMEZ-FOIX, A.M., ALAM, T., GERARD, R.D., and NEWGARD, C.B. (1994). Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43, 161-189.
6. BEHARA, A.M.P., WESTCOTT, A.J., and CHANG, P.L. (1992). Intrathymic implants of genetically modified fibroblasts. FASEB J. 6, 2853-2858.
7. BLAESE, R.M., CULVER, K.W., MILLER, A.D., CARTER, C.S., FLEISHER, T., CLERICI, M., SHEARER, G., CHANG, L., CHIANG, Y., TOLSTESHEV, P., GREENBLATT, J.J., ROSENBERG, S.A., KLEIN, H., BERGER, M., MULLEN, CA., RAMSEY, W.J., MUUL, L., MORGAN, R., and ANDERSON, W.F. (1995). T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270, 475-480.